| Schedule of Net Loss and Adjusted EBITDA |
The following tables set forth the Company’s net loss and adjusted EBITDA for the three- and six- months ended June 30, 2026 and 2025: | | | Three Months Ended
June 30, | | | Six Months Ended
June 30, | | | (In US$, unless otherwise stated) | | 2026 | | | 2025 | | | 2026 | | | 2025 | | | Net loss (GAAP) | | $ | (115,227,348 | ) | | $ | (2,902,313 | ) | | $ | (118,786,726 | ) | | $ | (7,725,194 | ) | | Adjustments | | | | | | | | | | | | | | | | | | Net interest (income) expense | | | (477,253 | ) | | | (12,805 | ) | | | (512,778 | ) | | | (42,915 | ) | | Depreciation and amortization expenses | | | 335,966 | | | | 180,787 | | | | 646,233 | | | | 349,836 | | | EBITDA | | | (115,368,635 | ) | | | (2,734,330 | ) | | | (118,653,271 | ) | | | (7,418,272 | ) | | Adjustments | | | | | | | | | | | | | | | | | | Share based compensation within | | | | | | | | | | | | | | | | | | Research and development | | | 436,808 | | | | 261,285 | | | | 676,982 | | | | 2,778,608 | | | Selling and marketing | | | 46,320 | | | | 65,299 | | | | 92,386 | | | | 170,448 | | | General and administrative | | | 509,959 | | | | 130,294 | | | | 839,994 | | | | 437,675 | | | Change in fair value of derivative liabilities | | | 108,294,223 | | | | - | | | | 105,317,692 | | | | - | | | Business combination and post-closing expenses | | | 622,980 | | | | 214,101 | | | | 2,164,930 | | | | 214,101 | | | Adjusted EBITDA | | $ | (5,458,343 | ) | | $ | (2,063,351 | ) | | $ | (9,561,286 | ) | | $ | (3,817,439 | ) |
|